Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rank in Stocks #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Share Price
$5.54
Last synced: 2024-09-18
Market Cap
$38.76M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alimera Sciences, Inc. (ALIM)

Category

EPS for Alimera Sciences, Inc. (ALIM)
EPS as of June 2024 TTM: $-0.28
According to Alimera Sciences, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-0.28. At the end of 2022 the company had a EPS of $-2.59 an increase over its 2021 EPS that were of $-0.66.
EPS history for Alimera Sciences, Inc. from 2006 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.28 -64.56%
2023 $-0.79 -69.50%
2022 $-2.59 292.42%
2021 $-0.66 -36.54%
2020 $-1.04 -52.51%
2019 $-2.19 -158.40%
2018 $3.75 -176.06%
2017 $-4.93 -47.66%
2016 $-9.42 -8.90%
2015 $-10.34 -22.43%
2014 $-13.33 -45.14%
2013 $-24.30 158.24%
2012 $-9.41 -12.63%
2011 $-10.77 61.95%
2010 $-6.65 -98.48%
2009 $-437.12 -23.24%
2008 $-569.46 977.30%
2007 $-52.86 -56.02%
2006 $-120.18 0.00%
EPS for similar companies or competitors